Compare Amphastar Pharmaceuticals Inc (AMPH) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs LyondellBasell Industries NV — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while LyondellBasell Industries NV trades at $57.39 (market cap $18.19B). The key difference: LyondellBasell Industries NV is far larger — about 22× Amphastar Pharmaceuticals Inc's market cap, and LyondellBasell Industries NV pays a 7.31% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LYB | |
|---|---|---|
Market Cap | $826.08M | $18.19B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $82.38 |
52-Week Low | $16.87 | $42.28 |
Enterprise Value | $1.22B | $29.81B |
Dividend Yield | — | 7.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
LYB trades at $56.36, up 1.74% today, with a bearish technical signal and mixed earnings history including a recent Q1 2026 beat. The company shows declining revenue and negative net income margins, though it maintains positive operating cash flow and recently announced a partnership for recycled-content packaging with Mondelez. Analyst consensus is a Buy with a $73.11 price target, indicating potential upside from current levels.
Outlook remains cautious due to profitability challenges and elevated debt, but cost-cutting and strategic shifts toward higher-margin polymers offer recovery potential. Key risks include persistent margin pressure and macroeconomic sensitivity, while institutional sentiment is divided between growth optimism and fundamental concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
